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Chromobox homolog 2 (CBX2) is a chromatin modifier that plays an important role in sexual
development and its disorders (disorders of sex development [DSD]), yet the exact rank and
function of human CBX2 in this pathway remains unclear. Here, we performed large-scale map-
ping and analysis of in vivo target loci of the protein CBX2 in Sertoli-like NT-2D1 cells, using the
DNA adenine methyltransferase identification technique. We identified close to 1600 direct tar-
gets for CBX2. Intriguingly, validation of selected candidate genes using qRT-PCR in cells overex-
pressing CBX2 or in which CBX2 has been knocked down indicated that several CBX2-responsive
genes encode proteins that are involved in DSD. We further validated these effects on the candi-
date genes using a mutated CBX2 causing DSD in human patient. Overall, our findings suggest
that CBX2 role in the sex development cascade is to stimulate the male pathway and concurrently
inhibit the female pathway. These data provide fundamental insights into potential etiology of
DSD. (Molecular Endocrinology 29: 247–257, 2015)
The process of sexual differentiation is central for re-production in almost all metazoan and, therefore, for
maintenance of practically all multicellular organisms.
The critical step in this process is the determination of the
bipotential embryonic gonad into either ovaries or testes.
Defects in any of the genes involved in either the testicular
or ovarian development can result in disorders of sex
development (DSD) (1, 2). Although there have been con-
siderable advances in our understanding of the genetic
factors involved in sexual differentiation, the fact remains
that in most DSD the underlying genetic cause is un-
known, in fact, it has been estimated that a molecular
diagnosis is made in only about 20% of DSD (3, 4). This
highlights the substantial gap in knowledge that needs to
be addressed.
Chromobox homolog 2 (CBX2) was recently added as
an additional player in human sex development process
(5). CBX2 and its mouse homologueM33 aremembers of
the polycomb (PcG) family of proteins. PcG proteins are
highly conserved transcriptional regulators that form
large multiprotein complexes, which exert their function
through the modulation of higher order chromatin struc-
ture (6, 7). They are required for stable maintenance of
gene expression programs through developmental and
cell differentiation processes. Although best known for
their role in controlling the expression of Hox genes in
Drosophila during development, numerous PcG mem-
bers have been now implicated in the control of various
cellular processes, such as chromosome X-inactivation,
cell fate decisions, tumorigenesis, and sexual differentia-
tion (8–12). Human CBX2 exists in 2 isoforms, a 532-
amino acid long isoform (NP_005180), called CBX2.1
(hereafter referred to as CBX2), and a second shorter
211-amino acid isoform (NP_116036), named CBX2.2.
The importance of M33/CBX2 for sexual development is
highlighted by the fact that M33-deficient mice have
male-to-female sex reversal (13). Similarly, in humans, we
made the intriguing discovery of a CBX2 loss-of-function
ISSN Print 0888-8809 ISSN Online 1944-9917
Printed in U.S.A.
Copyright © 2015 by the Endocrine Society
Received October 28, 2014. Accepted December 26, 2014.
First Published Online January 8, 2015
Abbreviations: CBX2, chromobox homolog 2; ChIP, Chromatin Immuno Precipitation;
Dam, DNA adenine methyltransferase; DamID, Dam identification; DSD, disorders of sex
development; EcoDam-CBX2, pLgw-EcoDam-V5-CBX2; NGS, next-generation sequenc-
ing; PcG, Polycomb; siRNA, small interference RNA; SRY, Sex determing Region of the Y
chromosome; TSS, transcription start site; WES, Whole Exome Sequencing; WNT4, Wing-
less-type MMTV integration site family, member 4; WT, wild type; WT1, Wilms tumor
protein-1.
O R I G I N A L R E S E A R C H
doi: 10.1210/me.2014-1339 Mol Endocrinol, February 2015, 29(2):247–257 mend.endojournals.org 247
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 05 February 2016. at 04:48 For personal use only. No other uses without permission. . All rights reserved.
double heterozygote mutation state in a 46, XY girl with
ovarian tissue at histology, normal uterus, and external
genitalia, accidently diagnosed because of discrepancy be-
tween prenatal karyotypes and phenotype at birth. Func-
tional studies demonstrated that the mutated CBX2 does
not properly bind to and does not adequately regulate the
expression of target genes essential for sex development
such as SF1/NR5A1 (5), which was in agreement with
other data (14).
Although these data elucidated that CBX2 is involved
in the molecular pathogenesis of DSD and that it lies
upstream of SRY (Sex determining Region of the Y chro-
mosome) in the sex determination cascade, little is known
about the exact rank of CBX2 and its role in this cascade.
To gain insight into CBX2 function, we have employed
the DNA adenine methyltransferase (Dam) identification
(DamID) coupled with next-generation sequencing
(NGS) to analyze the humanCBX2 localization across the
genome and identify its direct targets.
In this study, we identified close to 1600 direct targets
of CBX2 in human Sertoli-like cells. Furthermore, we
provide evidence that the expression of some of the iden-
tified targets is CBX2 dependent, thereby identifying po-
tential genes that could be involved in DSD in humans
and setting the ground for future studies.
Materials and Methods
Cell culture
HEK293T (ATCC CRL-11268) and NT2-D1 (ATCC CRL-
1973) cells were obtained from the American Type Culture Col-
Figure 1. The DamID platform for location analysis of human CBX2. A, Dam-CBX2 localizes to the nucleus. NT2–D1 cells were transfected with
the Dam-V5-CBX2; 48 hours later, cells were detergent extracted and fixed. Dam-V5-CBX2 was visualized by indirect immunofluorescence using a
V5 antibody, nuclei were visualized by DAPI. Scale bar, 5 m. B, Immunoblot analysis of Dam-V5-CBX2 expression in NT2–D1 cells. Whole-cell
extracts of cells transfected with same construct as in A were analyzed by immunoblotting for the expression of Dam-V5-CBX2 using a monoclonal
antibody against V5; tubulin is used as a loading control. C, Identified enriched regions localize relatively close to TSSs. In a 5-kb window around
the TSS are 2 peaks in the distribution. The highest peak reflects binding events in the promoter region. Considering all identified putative binding
regions there is a general peak close to a TSS.
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lection and cultured at 37°C, 5% and 10%CO2, respectively, in
DMEM containing 10% fetal bovine serum and supplemented
with penicillin-streptomycin.
Small interference RNA (siRNA)
siRNA duplexes were purchased from Microsynth, siRNA se-
quences are as follows: (si scrambled) (CGUACGCGGAAUAC-
UUCGATT) (15), CBX2–145 (GGCUGGUCCUCCAAACAUA-
TT), and CBX2-411 (GGAUGACAGUGAGUUAGAUTT) (5).
siRNA duplexes were introduced into cells using Lipofectamine
RNAiMAX (Invitrogen) in 2 consecutive rounds at a final concen-
tration of 40nM. Experiments were typically performed 48 hours
after the first transfection. For targets that did not show a signifi-
cant change in expression at 48 hours, experiments were repeated
at 72 hours.
Immunofluorescence
Cells grown on cover slips were preextracted for 5 minutes
on ice using 25mM HEPES (pH 7.4), 50mM NaCl, 1mM
EDTA, 3mMMgCL2, 300mM sucrose, and 0.5%TritonX-100
before fixation in 4% formaldehyde (wt/vol) in PBS for 15 min-
utes at room temperature. Cover slips were incubated overnight
at 4°C with primary antibodies and Alexa Fluor-conjugated
secondary antibodies (check Supplemental Information for de-
tailed antibodies information) for 1 hour at room temperature.
The cover slips were mounted with Vectrashield (Vector Labo-
ratories) containing DAPI (4=,6-diamidino-2-phenylindole). Im-
ages were acquired using a Nikon eclipse Ni-E microscope
system.
Dam identification
DamID was performed using the lentiviral transduction
protocol as previously described (16), using pLgw-EcoDam-V5-
CBX2 (EcoDam-CBX2) or pLgw-V5-EcoDam. Briefly, EcoDam-
CBX2 or pLgw-V5-EcoDam was transfected into HEK239T
cells together with the packaging plasmids (pRSV-Rev, pCMV-
dR8.2, pMD2.G) using Metafectene (Biontex Laboratories); 48
hours later, the supernatant containing the lentivirus was har-
vested and added to NT-2D1 cells with polybrene 1 mg/mL
(Santa Cruz Biotechnology, Inc), and 2 consecutive rounds of
transduction were performed. Two days after the first infection,
genomic DNA was isolated using DNeasy blood and tissue kit
(QIAGEN). The isolated gDNA was subject to DpnI digestion,
ligation of DamID adaptors andDpnII digestion. Samples with-
out addition of DpnI or ligation adaptors served as negative
controls. DpnII-digested fragments were used as templates to
amplify methylated genomic fragments.
Next-generation sequencing
Library preparation was performed using standard proce-
dures, see Supplemental Methods for a detailed protocol. The
sequence alignment to the human genome (hg19) was per-
formed with Bowtie2 using the options “sensitive” and
“nondeterministic.” To identify peaks from the data, we used
MACS (version 1.4) with default options. The subsequent anal-
ysis, including the annotation and visualization of peaks, was
done with the Bioconductor-packages ChIPpeakAnno and Gviz
from R.
Quantitative real-time PCR
Total RNA was extracted using the RNeasy Mini kit
(QIAGEN) and reverse transcribed using the Omniscript re-
verse-transcription system (QIAGEN). Experiments were per-
formed with an ABI StepOnePlus Real-Time PCR system, PCR
products were quantified fluorometrically using the KAPA
SYBR FAST master mix (KAPA Biosystems). The reference
mRNA cyclophillin was used for normalizing the data (primers
sequence available upon request). All samples were run in trip-
licates. Unpaired t test was performed using GraphPad Prism
version 5.04 for Windows, GraphPad Software.
Results
Mapping of CBX2 target loci
To gain insights into the function of CBX2 and to
identify its targets, we applied the DamID-sequencing
Figure 2. Genomic binding features of CBX2. A, Localization of identified enriched binding regions in relation to described gene models. B, The
enriched regions are representing different genomic features. Based on the overlap, an identified region can be assigned to more than 1 feature
type. The promoter region is defined as 5 kb upstream of a TSS.
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method that couples NGS to DamID assay. DamID is a
methodology independent of antibodies, fixation, chro-
matin shearing, and other technically challenging features
of chromatin immunoprecipitation, a technique com-
monly used to explore DNA/protein interactions. It has
proven to be a powerful tool for the mapping of genomic
binding sites of chromatin proteins (16). First, we teth-
ered humanCBX2 toEscherichia coliDam and expressed
the fusion protein in human testis-derived NT-2D1 cells.
In eukaryotic cells that lack endogenous Dam proteins,
the tethered Dam is capable of methylating adenines in
GATC sequences that are in close spatial proximity (17).
We confirmed by Western blotting and immunofluores-
cence that the exogenously introduced CBX2-Dam fusion
protein was expressed and properly localized to the nu-
cleus (Figure 1, A and B). Next, we transduced NT-2D1
cells with the lentivirus expressing Dam-CBX2, purified
the gDNA from transduced cells, specifically amplified
the methylated DNA fragments, and sequenced them.
Cells expressing free Dam protein served as a control to
Figure 3. Identified peak regions of validated target genes. The coverage profile of the peak region normalized by the control sample is shown
for selected validated target genes. The genomic coordinates are indicating the peak region. The distance (d) to the TSS of the target gene is
provided.
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correct for the unspecific DNA accessibility byDam alone
and for sequencing biases. We prepared 2 replicates for
each fusion protein or free Dam and sequenced the DNA
libraries separately. All pairs of replicates had highly cor-
related read densities along the genome (Pearson correla-
tion coefficients  0.90, P  2e-16) and thus were com-
bined for the follow-up analyses. In total, we obtained 85
million and 17 million reads from NT-2D1 expressing
Dam-CBX2 and free Dam, respectively. After peak-call-
ing, we identified 1595 direct targets of CBX2 with a P
1e-5 (Supplemental Table 1).
In order to elucidate the detailed distribution of CBX2
binding, we analyzed the identified putative target regions
of CBX2. The distance to the closest transcription start
site (TSS) showed that most of the called peaks is nearby
a TSS (Figure 1C). A detailed view on the 5-kb up- and
downstream region around the TSS showed depletion in
the actual start site, whereas the largest peak is located in
the promoter region of the putative target genes (Figure
1C). Analysis of the putative CBX2 binding sites (Figure
2A) confirms that most peaks are upstream to the closest
TSS. The fraction of peaks found in the promoter region
defined by 5 kb upstream is rather small (3%) (Figure
2B). In contrast, many peaks (65%) are located in in-
tergenic regions (Figure 2B and 3).
Validation of CBX2 targets
To independently test the DamID-seq results, we se-
lected a subset of CBX2 targets identified by DamID-seq
for further investigation and validation. Target selection
was based on their reported putative involvement in sex-
ual differentiation, their biological role in human disease
and animal models, or their specific expression in tissues
involved in sex development (gonads, sex organs, hypo-
thalamus, and pituitary) (Table 1). Applying these selec-
tion criteria, we shortlisted 19 genes. In basal (control)
conditions, expression analysis showed that NT2-D1
cells endogenously expressed fifteen of these genes
(SOX9, MAMLD1, EXO1, SOX3, TEX10, TBX2,
PBX1, TSNAX, FGF2, FGFR2, ATRX,WTAP,MTM1,
TSPYL4, and FZD1), whereas 4 genes, namely KISS1,
ZP4, PASD1, and IGF1, were not significantly expressed
in this particular cell line. (Figures 4 and 5 and data not
shown). To study the influence of CBX2 on the expres-
sion of the selected genes, we measured their expression
levels in NT2-D1 cells under overexpression and upon
selectively knocking down endogenous CBX2 using spe-
cific siRNAs (5), respectively. The expression level of
CBX2 upon its exogenous overexpression or knock-
down was confirmed at the protein and mRNA levels by
Western blot and qRT-PCR (quantitative Reverse Tran-
scriptase-Polymerase Chain Reaction) analyses, respec-
tively (Supplemental Figure 1).
As a prelude for validating the candidate target genes,
we first checked the effect of CBX2 on genes known to be
regulated by it such as SOX9, SF1, and SRY (5, 11).
SOX9 was among the identified targets in our DamID-
seq. Compared with control transfection (empty vector),
overexpression of CBX2 enhanced expression of SOX9,
SF1/NR5A1, and SRY by 4-, 3-, and 3-fold, respectively,
whereas knocking down endogenous CBX2 resulted in
down-regulating the expression of the same genes to 0.6-,
0.5-, and 0.6-fold, respectively (Supplemental Figure 2),
consistent with previous observations (5).
Next, we examined the effect of CBX2 on the selected
candidate genes. The wild-type (WT) CBX2 significantly
enhanced the expression of endogenous EXO1, SOX3,
MAMLD1, TBX2, TEX10, FGF2,WTAP, TSPYL4, and
MTM1 (by 2.9-, 2.6-, 2.6-, 2.3-, 2.2-, 2.4-, 1.6-, 2.2-, and
1.6-fold, respectively) but decreased the expression of
PBX1 and FZD1 (to 0.5-, and 0.7-fold, respectively) (Fig-
ures 4 and 5). The expression of TSNAX, FGFR2, and
ATRX seemed not to be affected by CBX2 (Supplemental
Figure 3). To further explore the specificity of these ob-
servations, we knocked down endogenous CBX2 expres-
sion by siRNA oligos. Expression analysis showed that
down-regulation of CBX2 significantly reduced the ex-
pression of EXO1, SOX3, MAMLD1, TBX2, TEX10,
and TSPYL4 (to 0.7-, 0.6-, 0.6-, 0.6-, 0.7-, and 0.8-fold,
respectively) while enhancing the expression ofPBX1 and
FZD1 (by 1.9-, and 1.4-fold, respectively), compared
with control (scrambled siRNA), further supporting the
CBX2-dependent expression of these genes. The lack of
significant effects on the expression of MTM1, WTAP,
and FGF2 after down-regulating CBX2 is unclear, but it
might be attributed to redundant pathways controlling
the expression of these particular genes. Expression anal-
ysis for MTM1, WTAP, and FGF2 were reexamined at
different time points of CBX2 down-regulation and no
significant change in their expression levels were observed
(data not shown).
In whole-transcriptome studies in NT2-D1 cells, we
observed that CBX2 negatively regulates FOXL2 expres-
sion (our unpublished data). The validation of this results
showed a slight but significant reduction in the expression
of FOXL2 in response to overexpressed CBX2 and, re-
ciprocally, a significant up-regulation of its expression
when CBX2 was knocked down (Figure 5).
To study the pathophysiological consequences of
CBX2 defects, we took advantage of the mutations that
we described as being the molecular basis of 46, XY DSD
doi: 10.1210/me.2014-1339 mend.endojournals.org 251
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 05 February 2016. at 04:48 For personal use only. No other uses without permission. . All rights reserved.
in human patients (5) and repeated the experiments by
introducing the mutated forms of CBX2 harboring
P98L and R443P mutations into NT2-D1. Immunoflu-
orescence imaging showed that both mutated forms
localize to the nucleus, and qRT-PCR analysis sug-
gested that there are no significant differences in ex-
pression between WT and mutated CBX2 (Supplemen-
tal Figure 4). In contrast to WT CBX2, the mutated
CBX2 had no effect on the expression of all the selected
targets and behaved essentially as the control (Figures 4
and 5).
Discussion
Chromatin regulators are critical integration points
wherein biological signals are converted into changes in
gene expression. These protein machineries are essential
to normal cell function, development, and differentiation
(18). Critical for understanding the biology of these reg-
ulators is the determination of their binding sites to de-
duce their actions within the genome and eventually un-
derstand how the subsequent cellular responses occur.
This is of particular importance in case of DSD, where
Figure 3. (Continued).
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albeit the advance in understanding the genetic basis of
human sexual determination and differentiation, in most
subjects with DSD the underlying genetic cause is un-
known. Although pathogenic mutations have been identi-
fied in DSD patients, the phenotype can be highly variable,
evenwithin families, suggesting that other factors, including
genetic variants, are influencing the expression of the phe-
notype (3).UnexplainedDSDcasesmaybedue tomutations
in novel gonad-determining genes, or genomic alterations
affecting regulatory regions that lead to atypical gene ex-
pression. The identification of new genes involved in sex
determination is therefore a goal of the utmost importance
to the understanding of DSD and will allow for more accu-
rate diagnosis and clinical management of these complex
conditions (2).
To this goal, we chose to generate the first genome-wide
binding data for humanCBX2, a chromatinmodulator that
was shown to be involved in sex development in mice (11)
and humans (12). To explore its precise position in this de-
velopmental cascade, we employed the DamID assay cou-
pled with NGS (DamID-seq) that enabled us to identify
1595 direct targets for CBX2 in the human Sertoli-like cells
NT-2D1. To further refine our identification of targets, and
to place these genes in the context of the sexual determina-
tion pathway, we performed expression profiling experi-
ments on a subset of genes in cells overexpressing CBX2 or
in cells, in which endogenous CBX2 has been selectively
knocked down.
Among the factors known to play a role in male sex
development, we found SOX9 to be among our identified
targets of CBX2. SOX9 is the first identified target of
SRY, and its expression is essential for testis development
(19). SOX9 expression has been linked to CBX2 inmouse
studies (11), as well as in human cells (5), yet it remained
unclear whether CBX2’s influence on SOX9 is direct or
indirect. By identifying SOX9 sequences as targets for
CBX2 binding, our finding establishes the first direct link
between CBX2 and SOX9. Accordingly, the expression
of SOX9 was increased by approximately 4-fold upon
overexpressing CBX2, while decreased to 0.6-fold upon
knocking down endogenous CBX2, which is agreement
with previous data (5).
Numerous genes identified by our DamID-seq were
linked to DSD in humans: MAMLD1, SOX3, FGFR2,
Table 1. CBX2 Targets Selected for Expression Profiling
Gene
Symbol Gene Name Function Link to Sex Development
Fold Change
Upon CBX2
Overexpression
(EV  1)
Fold Change
Upon CBX2
Knockdown
(siScr  1)
SOX9 SRY (sex determining region Y)-box 9 Downstream target of SRY Mutation lead to 46, XY DSD (12) 1 4.0 2 0.6
MAMLD1 Mastermind-like domain-containing
protein 1
Transactivates the HES3 promoter
independently of NOTCH proteins
Mutation leads to hypospadia (40) 1 2.6 2 0.6
TEX10 Testis-expressed sequence 10 protein Functions as a component of the Five Friends of
Methylated CHTOP (5FMC) complex
Downstream binding target of
SRY (20)
1 2.2 2 0.7
EXO1 Exonuclease 1 Essential for male and female germ cells meiosis Loss leads to male and female
sterility (23)
1 2.9 20.7
SOX3 Transcription factor SOX-3 Required during the formation of the hypothalamo-
pituitary axis
Mutation leads to 46,XX DSD (41) 1 2.6 2 0.6
TBX2 T-box transcription factor TBX2 Involved in the transcriptional regulation of genes
required for mesoderm differentiation
Might be involved in development of
the reproductive system (21)
1 2.3 2 0.6
PBX1 Pre-B-cell leukemia transcription
factor 1
Transcriptional activator Loss leads to reduced urogenital ridge
outgrowth and absence of Müllerian
ducts (35)
2 0.5 1 1.9
FGFR2 Fibroblast growth factor receptor 2 Tyrosine-protein kinase that acts as cell-surface
receptor for fibroblast growth factors
Loss leads to partial XY sex
reversal (42)
n.s. n.s.
FGF2 Fibroblast growth factor 2 Potent mitogen and neurotropic factor for brain
cells in vitro
Ligand of FGFR2 1 2.4 n.s.
WTAP WT1-associated protein Impairs WT1 DNA-binding ability and inhibits
expression of WT1 target genes.
Mutation might be involved in
hypospadias (43)
1 1.6 n.s.
ATRX Transcriptional regulator ATRX Global transcriptional regulator XY patients with deletions or
mutations have varying degrees of
sex reversal (44)
n.s. n.s.
MTM1 Myotubularin Lipid phosphatase Deletion leads to myotubular
myopathy and abnormal genital
development (25)
1 1.6 n.s.
TSPYL4 Testis-specific Y-encoded-like protein 4 Belongs to the nucleosome assembly protein
(NAP) family
TSPYL mutation leads to sudden infant
death and dysgenesis of the
testes (22)
1 2.2 2 0.8
FZD1 Frizzled-1 Receptor for Wnt proteins Loss leads to sterility in females (30) 2 0.7 1 1.4
TSNAX Translin-associated protein X Acts in combination with TSN as an
endonuclease involved in the activation
of the RNA-induced silencing complex (RISC)
Null male mice have abnormal
seminiferous tubules and reduced
sperm count. Null female mice are
subfertile (45)
n.s. n.s.
The 2 right most columns indicate the behavior of the candidate target gene in response to CBX2 as up (1)- or down (2)-regulated. Change in
expression are represented as relative to control  1. EV, empty vector; siScr, si scrambled; n.s., nonsignificant.
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and ATRX (2), but their link to CBX2 is a novel finding.
In addition, further analysis of the genomic landscape
surrounding CBX2 revealed a number of additional gene
candidates, such as TEX10, EXO1, TBX2, TSPYL4,
WTAP, and MTM1, suggesting an additional role of
CBX2 in sexual development. For example, TEX10 has
been found to be a downstream binding target of SRY
(20).TBX2 is involved in the transcriptional regulation of
genes required for mesoderm differentiation, is overex-
pressed in reproductive system cancers, and has been sug-
gested to play a role in the development of themammalian
reproductive system (21), whereas TSPYL4 was reported
to be potentially linked to testicular dysgenesis (22).
EXO1 is essential for male and female meiosis, with
Exo1/ mice being sterile (23). WTAP functions by
impairing Wilms tumor protein-1 (WT1) DNA binding
and inhibits expression of WT1 target genes (24).MTM1
deletion has been associated with myotubular myopathy
and abnormal genital development (25).
We were unable to detect any significant changes in ex-
pression of FGF2,WTAP, andMTM1 after knockdown of
CBX2, despite the fact that their expression levels were sig-
nificantly increased upon overexpressing CBX2. According
to these results, CBX2 may only have an secondary role in
the regulation of these genes. However, it should be noted
that the siRNA-mediated knockdown of CBX2, although
substantial, may have been insufficient or not long enough
to cause detectable alteration in gene expression.
Few of our identified genes (TSNAX, FGFR2, and
ATRX) showed no significant change in expression levels in
response to CBX2 overexpression or knockdown. For
ATRX, a previous study reported a similar observation,
where the expression of the murine Atrx was not signifi-
cantly affected inM33/CBX2knockoutmice (11). This sug-
Figure 4. Genes up-regulated in a CBX2-dependent manner. qRT-PCR quantification of mRNA levels for putative CBX2 targets that are up-
regulated by CBX2. NT2–D1 cells transfected with empty vector (mock, white) or WT CBX2 (black) or mutant CBX2 (narrow lines) or scrambled
siRNA (wide lines) or siRNA against CBX2 (gray). Relative expression levels of target genes were determined by qRT-PCR after normalization to
cyclophillin as an endogenous control. After CBX2 overexpression (black), the relative expression of MAMLD1, TEX10, EXO1, SOX3, TBX2, FGF2,
WTAP, MTM1, and TSPYL4 was up-regulated compared with cells transfected with empty vector (white). CBX2 knockdown using siRNA (gray)
reduced the relative expression of MAMLD1, TEX10, EXO1, SOX3, TBX2, and TSPYL4 while not significantly affecting the expression of FGF2,
WTAP, andMTM1, compared with scrambled siRNA (wide lines). Introducing the mutated forms (P98L and R443P) of CBX2 (narrow lines) in equimolar
amounts into the cells showed no effect on the expression of all the target genes. The data in all graphs are the average of 3 independent experiments,
error bars represent SD, and values are expressed as relative to control 1. ****, P .0001; ***, P .001; **, P .01; *, P .05.
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gests that additional factors, perhaps coactivators and chro-
matin state, are involved in their transcriptional regulation.
In the same lineof reasoning,weobserved that among the
identified CBX2 targets are other transcription factors
(TBX2 and ATRX). Accordingly, previous reports sug-
gested that CBX2 regulates other genes, particularly SRY in
an indirect fashion through the regulation of other genes
encoding transcription factors (11). We and others (11)
could not find a direct interaction between CBX2 and SRY
that could explain the enhanced expression of SRY in
response to CBX2. It is intriguing to speculate the as-
sociation of any of the identified transcription factors
in the CBX2-dependent SRY regulation. Supporting
this idea, 2 recent studies in rats lacking the Y chromo-
some and the SRY gene suggested that additional copies
of CBX2 in males might be involved in a novel sex-
determining mechanism in species that lack SRY (26,
27). This observation underlines the central role of
CBX2 in male sexual development
as a factor independent from SRY,
although additional work is still
needed in this perspective.
We also identified CBX2 binding
near a considerable number of genes
encoding microRNAs, implying a
possible still undiscovered role of
microRNAs in human sex develop-
ment, similarly to what has been
shown for microRNAs and testicu-
lar proteome in mice (28), as well as
in gonadal sex differentiation in
chicken embryos (29). Further char-
acterization of the impact of CBX2
activation on microRNAs and their
potential involvement in sexual de-
velopment in humans is essential.
Among the identified targets,
there were also factors involved in
female sex development, such as on
FZD1 and PBX1. Fzd1 encodes a
wingless-type MMTV integration
site family (WNT) receptor whose
expression is markedly induced in
both mural granulosa cells and cu-
mulus cells during the preovulatory
period, in a manner similar to Wnt4
(30). WNT4 is a secreted protein es-
sential for female sex development, in
that it suppresses male sexual differ-
entiation in mice and patients (31,
32). In humans, additional copies of
WNT4 have been associated with
male-to-female sex reversal and WNT4 loss of function
causes DSD in women (33, 34). In a recent mouse study,
Fzd1 has been showed to be required for normal female
fertility,withFzd1/ females sterile or subfertile (30). Pre-
B-cell leukemia transcription factor 1 (PBX1), which we
found to be negatively regulated by CBX2, has been shown
to play a role in female internal sex organ differentiation. In
mice, the loss of Pbx1 resulted in absence ofMüllerian ducts
(35). In the same context,weobserved thatCBX2negatively
regulatesFOXL2 expression. FOXL2 is considered tobe the
female counterpart of SOX9 (36). In this regard,we hypoth-
esize that CBX2 functions, at least in part, by actively re-
pressing ovarian development in XY gonads, which is in
agreement with previous data showing that mutations
in CBX2 causes male-to-female reversal with ovarian tissue
in SRY-positive mice (11) and in humans (5).
Interestingly, when we repeated the experiments by
introducing a mutated form of CBX2, we previously de-
Figure 5. Genes down-regulated in a CBX2-dependent manner. qRT-PCR quantification of
mRNA levels for putative CBX2 targets that are down-regulated by CBX2. NT2–D1 was treated as
in Figure 4. CBX2 overexpression (black) decreased the relative expression of PBX1, FOXL2, and
FZD1, compared with cells transfected with empty vector (white). Upon CBX2 knockdown (gray),
the relative expression of PBX1, FOXL2, and FZD1 were up-regulated upon comparing with
scrambled siRNA (wide lines). Transfecting the cells with equimolar amounts of the mutated
forms (P98L and R443P) of CBX2 (narrow lines) showed no effect on the relative expression of all
the target genes compared with control. The data in all graphs are the average of 3 independent
experiments, error bars represent SD, and values are expressed as relative to control  1.
****, P  .0001; ***, P  .001; **, P  .01; *, P  .05.
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scribed as the molecular basis of 46, XY DSD human
patient (5), there was no effect on all the selected targets
compared with the control, confirming the loss-of-func-
tion nature of the mutations and that the observed effects
on gene expression are CBX2 specific.
Taken together, our findings represent the first com-
prehensive genome-wide study of CBX2 binding coupled
with the expression profiling that further extends the role
of CBX2 in human sexual differentiation, and also unrav-
els the complexity and context dependence of CBX2-
modulated responses. In fact, it appears that CBX2 on
one hand acts in the testis by stimulating the expression of
male-specific genes, SOX9, and simultaneously sup-
presses the female pathway by negatively regulating
FOXL2 and the WNT4 pathway (Figure 6). The mecha-
nisms underlying this bifunctional role are speculation
but are most likely due to differences in the composition
of regulatory complexes (37) and confirm that, as nicely
put by Sekido and Lovell-Badge, “sex determination is a
story of opposing forces and crucial alliances. [. . . ]. It is
a matter of timing (and expression level) that determines
which pathway wins” (38). Moreover, our study shed
more light on novel and potential pathological mecha-
nisms that could be involved in DSD: further character-
ization of how these new targets fit into an expanding
CBX2-regulated network should reveal how CBX2 acti-
vation and suppression can impact our understanding of
DSD pathogenesis and ultimately DSD diagnosis and
management. Finally, because all these effects were abol-
ished when the mutated CBX2 was tested, the hypothe-
sized role of CBX2 as both a stimulator of male and
inhibitor of female pathway might help to explain the
presence of ovarian tissue in the gonads of our CBX2-
deficient 46, XYDSDpatient (5) and shed further light on
the possible mechanism of disease.
The future of clinical genetic analysis is doubtless NGS.
Nevertheless, whole-exon sequencing identifies around
23%–25% of the genetic causes of diseases (39), and the
percentage seems to be even lower inDSD (10%; personal
communication). Several reasons beside technical pitfalls
might be accounted for these results. For example, the cause
of the diseasemight be located outside the coding sequences,
the disease is not monogenic, and too many candidate vari-
ants remained after filtering or part of the mechanism of
disease can be ascribed to differences in gene regulation
rather than gene structure. Although whole-exon sequenc-
ing remains a valuable tool in DSD, the study of regulatory
networks is going to complementNGS in the understanding
of these conditions. Experiments like ours leading to the
discovery andunderstandingof pathways andnetworkswill
help “connecting the dots” in the interpretation of the NGS
studies.
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Figure 6. Potential role of CBX2 in the regulation of sex
development. The developmental stages plotted in relation to time, are
indicated as bipotential when both sexes are indistinguishable from
one another (except for their karyotype), sex determination as the
decision determined by several factors to develop into a male or a
female gonad, and sex differentiation, the step determining the actual
sexually dimorphic phenotype. In blue, the male and in pink the female
factors. The framed factors were found to be related to human
disease. Solid lines between CBX2 and its targets indicate a direct
interaction (binding of CBX2 on target’s DNA sequences). Green
arrows indicate stimulatory effects of CBX2 on the indicated target;
the red “t” indicates inhibitory effects. Broken lines indicate a
functional but not physical interaction (changes in expression without
direct binding). A black solid line indicates direct binding of CBX2 on
the target without any effect on expression. Because all these effects
were abolished when the mutated CBX2 was tested, the hypothesized
role of CBX2 as both a stimulator of male and inhibitor of female
pathway might help to explain the apparent presence of ovarian tissue
in the gonads of our CBX2 46, XY patient (5).
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